Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pimitespib with imatinib in advanced gastrointestinal stromal tumor
jRCT2011210044Phase 1Active, not recruiting
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Dec 2021
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of pimitespib, imatinib and sunitinib in gastrointestinal stromal tumor (GIST) (4 arms), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoints: Dose-limiting toxicity, Maximum tolerated dose and 1 more. Started Dec 2021; status: active, not recruiting.
02
Drugs
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on jRCT2011210044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011210044.